1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Civeo completed a private offering of $100 million in 4.50% convertible senior notes due 2031 on July 7, 2026, with an option for initial purchasers to buy up to an additional $15 million. The company used about $22.3 million of the net proceeds to repurchase 660,297 common shares and plans to use the rest to repay borrowings under its syndicated facility agreement.
Notes carry a 4.50% interest rate, payable semi-annually, and mature August 1, 2031
Net proceeds of about $96.2 million, after discounts and offering expenses
Initial conversion price of about $40.51 per common share; maximum of 2,962,080 shares issuable, or 3,406,392 if the option is fully exercised
Company may not redeem the notes before August 1, 2029, except for tax or cleanup redemptions
ResMed agreed on June 30, 2026 to sell its MatrixCare business to private equity firm Frazier Healthcare Partners for $490 million in cash, subject to closing adjustments. The company plans to use the proceeds to return capital to shareholders, including an accelerated share repurchase, and for general corporate purposes. The filing reiterates ResMed's fiscal 2026 outlook and says the full fiscal 2027 outlook will be given on August 6, 2026.
Buyer is Frazier Healthcare Partners; price is $490 million all-cash, subject to certain closing adjustments.
Deal is expected to close in the first quarter of fiscal 2027, subject to regulatory approvals and customary conditions.
MatrixCare had approximately $220 million of revenue and $55 million of non-GAAP operating profit in fiscal 2026, based on preliminary results.
Recently completed Noctrix acquisition is expected to add about $30 million of fiscal 2027 revenue and reduce non-GAAP diluted EPS by about $0.20.
CareDx completed the sale of its Lab Products business to Eurobio Scientific on June 30, 2026, and the acquisition of Naveris, maker of the NavDx cancer test, on July 1, 2026. The company will include Naveris in its consolidated results from the third quarter of 2026, and it plans to give financial impact details on the sale during its second quarter 2026 earnings call.
Eurobio sale closed June 30, 2026; the 8-K reports $171.7 million in cash, subject to customary adjustments, while the press release cites $171.2 million at closing.
Naveris acquisition closed July 1, 2026, for $161.8 million in cash, subject to adjustments, plus up to $100.0 million in contingent cash tied to 2026 and 2027 revenue milestones.
The press release says Naveris generated approximately $35 million in revenue in 2025 and that NavDx has Medicare coverage for HPV-driven head and neck and anal cancer MRD testing.
Financial statements of Naveris and pro forma information will be filed by amendment within 71 calendar days.
Iridium completed its acquisition of the remaining 61% of Aireon Holdings LLC on July 2, 2026, giving it full ownership of Aireon. The purchase price was approximately $366.7 million, with half paid in cash and the rest funded by a $183.36 million interest-free loan from the sellers, while Aireon's $154.7 million term loans now sit on Iridium's consolidated balance sheet. The filing also discloses cash retention awards for two executives tied to the pending Rocket Lab merger.
Purchase price of approximately $366.7 million, 50% paid in cash at closing on July 2, 2026
Sellers provided a $183.36 million interest-free term loan maturing one year after the closing date
Aireon's Term Loans had an aggregate principal balance of $154.7 million, maturing October 10, 2028
CFO Vincent J. O'Neill ($409,999.98) and CLO Kathleen A. Morgan ($873,036.32) received retention awards tied to the Rocket Lab merger agreement dated June 28, 2026
Oceaneering completed a private placement of $500 million of 6.875% senior notes due July 15, 2034 on July 6, 2026, and amended its senior secured revolving credit facility the same day. The notes satisfied the financing condition for a previously announced cash tender offer, and the amendment raised revolver commitments and extended their maturity, which the company says provides additional financial flexibility.
$500 million of 6.875% senior notes due July 15, 2034, sold to qualified institutional and non-U.S. buyers on July 6, 2026
Interest payable January 15 and July 15 each year, starting January 15, 2027; notes are unsecured senior obligations
Revolving credit commitments increased from $215 million to $345 million; maturity extended from 2027 to 2031
Financing condition for the cash tender offer described in the June 24, 2026 Offer to Purchase was satisfied on July 6, 2026
Public Storage's Chief Operating Officer, Chris Sambar, resigned effective at the end of July 2026 to become Chief Enterprise Officer at T-Mobile. The company said the departure was not related to any disagreement over its operations, policies, or practices, and that operations leadership will report to CEO Tom Boyle until a permanent replacement is named.
Chris Sambar resigned on July 2, 2026, effective at the end of July 2026
He is joining T-Mobile as Chief Enterprise Officer
No disagreement with the company on operations, policies, or practices, according to the filing
Operations leadership will report directly to CEO Tom Boyle until a permanent replacement is identified
MasTec entered a $700 million delayed draw term loan to help fund its planned acquisition of Electrical Specialists, Inc., d/b/a the Superior Group, and expanded its revolving credit commitments by $350 million to $2,250 million. The company also agreed to issue about 1,195,721 shares, valued at about $475 million, as partial acquisition consideration, which the filing says represents about 1.5% of outstanding shares.
Delayed draw term loan of $700 million: $400 million three-year tranche and $300 million four-year tranche, with Bank of America as administrative agent.
Revolving credit commitments increased by $350 million to an aggregate $2,250 million.
About 1,195,721 consideration shares valued at about $475,000,000, roughly 1.5% of outstanding shares after issuance, expected to close in the third quarter of 2026.
Director Manuel Benito Miranda appointed to the Board effective June 30, 2026, and to the Compensation Committee.
Suncrete's borrowing unit amended its Bank of America credit agreement on June 30, 2026, adding a $175.0 million delayed draw term loan and raising the revolving credit facility from $25.0 million to $50.0 million. The amendment also permits up to $400.0 million in net cash proceeds from equity issuances to fund permitted acquisitions and changes certain financial covenants.
Delayed draw term loan of $175.0 million available for drawings until December 31, 2027 or earlier termination, maturing July 29, 2029
Revolving credit facility increased from $25.0 million to $50.0 million; about $22.0 million outstanding as of June 30, 2026 after a roughly $7.0 million drawdown that day
Term loan outstanding was about $189.2 million after application of amendment proceeds; no delayed draw borrowings had been made as of the Effective Date
Senior net leverage covenant set at 4.00-to-1.00 through June 30, 2027, then 3.50-to-1.00 after September 30, 2027
Osprey Acquisition Corp. III, a blank check company, completed its initial public offering on July 2, 2026, selling 30,015,000 units at $10.00 each for gross proceeds of $300,150,000, including full exercise of the over-allotment option. The full $300,150,000 was placed in a trust account for public shareholders, and funds will generally not be released until a business combination, or redemption if none is completed within 24 months.
IPO of 30,015,000 units at $10.00 per unit, gross proceeds of $300,150,000, closed July 2, 2026
Private placement of 747,000 units to Cantor and the sponsor for gross proceeds of $7,470,000
Trust account funded with $300,150,000; funds generally held until a business combination or 24-month deadline
Board expanded to include Daniel C. Herz, Jonathan Z. Cohen and others; Jeffrey F. Brotman resigned from the board
T-Mobile appointed Chris Sambar, formerly Chief Operating Officer at Public Storage and a two-decade AT&T veteran, as Chief Enterprise Officer, effective no later than October 14, 2026. Chief Business and Product Officer Michael J. Katz is leaving his role effective July 8, 2026, and will remain as a strategic advisor through December 2026. The filing reports no financial results, so the changes affect shareholders through leadership structure rather than current numbers.
Chris Sambar joins as Chief Enterprise Officer, effective no later than October 14, 2026, reporting to CEO Srinivasan Gopalan
Michael J. Katz, Chief Business and Product Officer, steps away effective July 8, 2026, and stays as strategic advisor through December 2026
André Almeida moves to Chief Marketing, Brand and Broadband Officer; Dr. John Saw expands his role to include product engineering and cybersecurity
Genworth Financial said CEO Thomas McInerney is taking a temporary leave of absence to focus on his health. CFO Jerome Upton, who has been with the company since 1998, was named Interim President and Chief Executive Officer effective July 7, 2026. The filing does not describe how long the leave will last or any change to the company's strategy.
Thomas J. McInerney, President and CEO, began a temporary leave of absence on July 7, 2026 to focus on his health
Jerome T. Upton, 62, CFO since March 2023, was appointed Interim President and CEO effective July 7, 2026
Board Chair Melina Higgins said the company plans to continue executing its existing strategy during the interim period
Penguin Solutions reported third-quarter fiscal 2026 net sales of $478.7 million, up 48% from a year earlier, and GAAP diluted earnings of $0.68 per share compared with a loss of $0.01 per share. The company raised its full-year fiscal 2026 outlook for both net sales and earnings per share, citing AI-driven demand, which is a positive sign for shareholders on the company's headline measures.
Q3 fiscal 2026 net sales were $478.7 million, up from $324.3 million in the year-ago quarter; Integrated Memory sales were $275.1 million.
GAAP diluted EPS was $0.68 versus $(0.01) a year earlier; non-GAAP diluted EPS was $0.84 versus $0.47.
Full-year fiscal 2026 net sales growth outlook is now 22% plus or minus 2%, up from 12% plus or minus 5%; non-GAAP EPS outlook is now $2.60 plus or minus $0.05, up from $2.15 plus or minus $0.15.
Management will discuss results on a conference call and webcast today, July 7, 2026, at 1:30 p.m. Pacific Time.
DigitalOcean said in a July 7, 2026 press release that it expects Q2 2026 revenue growth of about 29%, up from 14% in the same quarter of 2025, and that its remaining performance obligations will exceed $800 million. The company also expects its adjusted EBITDA margin and non-GAAP net income per share to be at or above the high end of its previously provided guidance. These are preliminary, unaudited figures subject to quarter-end closing adjustments, so final results may differ.
Q2 2026 revenue growth expected at about 29%, versus 14% in Q2 2025
RPO expected to exceed $800 million, up more than $550 million in the quarter
Adjusted EBITDA margin and non-GAAP EPS expected at or above the high end of guidance
Secured an additional 20 MW of data center capacity for late 2027 and early 2028
EchoStar and Hughes Satellite Systems disclosed that Hamid Akhavan, CEO of EchoStar Capital and President and CEO of Hughes, resigned effective immediately on July 6, 2026, following discussions with the board about a change in strategic direction. Charles W. Ergen will take over his responsibilities as Principal Executive Officer of Hughes, and EchoStar Capital will be folded into Corporate Development led by Thomas A. Cullen.
Hamid Akhavan resigned July 6, 2026 from all positions with EchoStar and Hughes, including his board seats, citing a change of strategic direction discussed with the board.
Akhavan will consult with the company through December 31, 2026 to ensure an orderly transition.
Charles W. Ergen takes over as Principal Executive Officer of Hughes; the filing refers to EchoStar's other filings for his compensation and related-party transactions.
Akhavan's option vesting is accelerated from December 31, 2026 to July 6, 2026; EchoStar Capital merges into Corporate Development under Thomas A. Cullen.
On June 30, 2026, MeiraGTx entered a royalty note purchase agreement with funds affiliated with Oberland Capital for up to $375 million, secured by company assets and tied to capped royalties on three gene therapy products. The company also agreed to sell 950,570 shares at $10.52 for about $10.0 million and fully redeemed its Perceptive credit notes on the same day. The royalty obligation and asset security add long-term commitments for shareholders, though the funding is non-dilutive apart from the small equity sale.
Initial purchase of $100 million on June 30, 2026, with a second purchase of $25 million scheduled for July 17, 2026
Revenue Payments equal to 1.95% of global net sales of AAV-AIPL1, AAV-hAQP1 and bota-vec, subject to a cap and payable after marketing approval
Sale of 950,570 shares at $10.52 per share for about $10.0 million, with closing on July 17, 2026
Full redemption of Perceptive notes on June 30, 2026, with no early termination penalties
Compass Pathways reported 26-week results from the second Phase 3 COMP006 trial of COMP360 in treatment-resistant depression, saying they confirm rapid onset and durable response. The company said its rolling NDA submission is underway, with final submission expected in Q4 2026 and launch expected in the first half of 2027, subject to FDA approval and DEA rescheduling.
39% of participants in the 25 mg arm reached a clinically meaningful MADRS reduction of at least 25% by Week 6 and maintained benefit through at least Week 26
COMP006 enrolled 581 dosed participants; serious adverse events were 6.3% in the 1 mg arm and 5.7% in the 25 mg arm over 26 weeks
Final NDA submission is expected in Q4 2026, with launch anticipated in the first half of 2027 if FDA approved
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.